A recent study published in the International Journal of clinical practice depicted that ferric carboxymaltose (FCM) injection administered preoperatively without any other supplementation could reduce the need of red blood cell (RBC) transfusion in individuals undergoing total hip arthroplasty (THA).

A total of 1,032 patients undergoing unilateral THA from November 2014 to July 2018 were included in the retrospective study. They were divided into two groups. The FCM group included 568 patients and the non-FCM group included 464 patients. The primary endpoint was to evaluate the inter-group difference in the requirement of RBC transfusion.

The propensity-score matching method led to 389 patients in each group. It was observed that the amount and incidence of RBC transfusion in the FCM group were remarkably lower compared with the non-FCM group, as illustrated in Table 1: 

Thus, it was concluded that the single preoperative FCM administration can be recommended as an easy patient blood management strategy for reducing the RBC transfusion in THA.